OPEN END TURBO LONG - ZEALAND PHARMA | Real-time Bid/Ask 07:08:12 26/06/2024 pm IST | ||
| 4.81 EUR / 4.86 EUR | -0.72% |
|
| Current month | +229.05% | ||
| 1 month | +447.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 4.87 | +25.52% |
| 24/24/24 | 3.88 | +16.87% |
| 21/24/21 | 3.32 | +85.47% |
| 20/24/20 | 1.79 | -0.56% |
| 19/24/19 | 1.8 | +10.43% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 11:53 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG2C1F |
| ISIN | DE000MG2C1F9 |
| Date issued | 15/04/2024 |
| Strike | 534.1 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.14 € |
|---|---|
| Lowest since issue | 0.68 € |
| Spread | 0.05 € |
| Spread % | 1.03% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
888
DKK
Average target price
866.3
DKK
Spread / Average Target
-2.44%
- Stock Market
- Certificates
- Certificat
